SYRE vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGX
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs. Its Competitors
Spyre Therapeutics (NASDAQ:SYRE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Spyre Therapeutics has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.
Spyre Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ultragenyx Pharmaceutical had 53 more articles in the media than Spyre Therapeutics. MarketBeat recorded 57 mentions for Ultragenyx Pharmaceutical and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.65 beat Ultragenyx Pharmaceutical's score of 0.08 indicating that Spyre Therapeutics is being referred to more favorably in the media.
Spyre Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Spyre Therapeutics' return on equity of -77.46% beat Ultragenyx Pharmaceutical's return on equity.
Spyre Therapeutics presently has a consensus price target of $53.40, indicating a potential upside of 224.42%. Ultragenyx Pharmaceutical has a consensus price target of $83.64, indicating a potential upside of 202.54%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Spyre Therapeutics is more favorable than Ultragenyx Pharmaceutical.
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 15.4% of Spyre Therapeutics shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Spyre Therapeutics beats Ultragenyx Pharmaceutical on 12 of the 17 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 7/17/2025 by MarketBeat.com Staff
Free SYRE Stock Alerts